VALN
VALN clinical trials: Valneva SE
Every trial on ClinicalTrials.gov where Valneva SE is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 51
- Trials linked
- 44
- As lead sponsor
- 7
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
VALN on the catalyst calendar · VALN registry changes
- Primary completion Jul 31, 2024ActualPhase 2NCT06106581A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 YearsValneva Austria GmbH · Chikungunya Virus InfectionCompletedVALNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 31, 2026Sponsor estimateNo phase registeredNCT07254702Prospective Safety Cohort Study After VLA1553 Vaccination in Municipalities Selected for Participation in the VLA1553 Pilot Vaccination...Valneva Austria GmbH · Chikungunya Virus InfectionActive, not recruitingVALNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2027Sponsor estimateNo phase registeredNCT07414524VLA1553-403 Pregnancy Surveillance StudyValneva Austria GmbH · Chikungunya Virus InfectionEnrolling by invitationVALNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2027Sponsor estimateNo phase registeredNCT07347002Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in BrazilValneva Austria GmbH · Chikungunya Virus InfectionEnrolling by invitationVALNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 3, 2023ActualPhase 3NCT04838444Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)Valneva Austria GmbH · Chikungunya Virus InfectionActive, not recruitingVALNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 21, 2025ActualPhase 1NCT06334393Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in...Valneva Austria GmbH · ZikaCompletedVALNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 31, 2026Sponsor estimateNo phase registeredNCT07163845Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the...Valneva Austria GmbH · Chikungunya Virus InfectionActive, not recruitingVALNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 3NCT07133178A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy ChildrenValneva Austria GmbH · Chikungunya Virus InfectionWithdrawnVALNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 27, 2024ActualPhase 3NCT06028841A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV)Valneva Austria GmbH · Chikungunya Virus InfectionWithdrawnVALNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredPhase 3NCT00605085Safety and Tolerability of the Japanese Encephalitis Vaccine IC51Valneva Austria GmbH · Japanese EncephalitisCompletedVALNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2006ActualPhase 3NCT00604708Immunogenicity Study of the Japanese Encephalitis Vaccine IC51Valneva Austria GmbH · Japanese EncephalitisCompletedVALNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2007ActualPhase 3NCT00594958Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51Valneva Austria GmbH · Japanese EncephalitisCompletedVALNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 22, 2021ActualPhase 3NCT04786444Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy AdultsValneva Austria GmbH · Chikungunya Virus InfectionCompletedVALNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 10, 2021ActualPhase 3NCT04956224Safety and Immunogenicity of VLA2001 Adults Aged ≥56 YearsValneva Austria GmbH · SARS-CoV-2 Virus InfectionCompletedVALNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 19, 2021ActualPhase 3NCT04546724Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in AdultsValneva Austria GmbH · Chikungunya Virus InfectionCompletedVALNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 22, 2022ActualPhase 2/Phase 3NCT05364242VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 InfectionValneva Austria GmbH · SARS-CoV-2 InfectionCompletedVALNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 19, 2021ActualPhase 3NCT04864561COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222Valneva Austria GmbH · SARS-CoV-2 Virus InfectionCompletedVALNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 31, 2023Sponsor estimatePhase 2/Phase 3NCT05298644COVID-19 Paediatric VLA2001-321 StudyValneva Austria GmbH · SARS-CoV-2 InfectionWithdrawnVALNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 26, 2021ActualPhase 1/Phase 2NCT04671017Dose Finding Study to Evaluate The Safety, Tolerability and Immunogenicity of an Inactiviated, Adjuvanted SARS-CoV-2 Virus Vaccine...Valneva Austria GmbH · SARS-CoV-2 Virus InfectionCompletedVALNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2011ActualPhase 3NCT01041573Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric PopulationValneva Austria GmbH · EncephalitisCompletedVALNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 26, 2018ActualPhase 2NCT03576183Study Confirming A Human Challenge Model and Investigating The Safety Of VLA1701Valneva Austria GmbH · Enterotoxigenic Escherichia Coli InfectionCompletedVALNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2013ActualPhase 3NCT01047839Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic CountriesValneva Austria GmbH · EncephalitisCompletedVALNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2012ActualPhase 3NCT01246479Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic...Valneva Austria GmbH · Japanese EncephalitisCompletedVALNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 13, 2018ActualPhase 1NCT03382964Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy VolunteersValneva Austria GmbH · ChikungunyaCompletedVALNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 26, 2018ActualPhase 1NCT03425149Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in...Valneva Austria GmbH · Zika VirusCompletedVALNLeadEBSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 26 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner